Mommox (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside nasal mucosal cells. This interaction alters gene expression, suppressing the production of inflammatory cytokines, prostaglandins and leukotrienes, and limiting the migration of inflammatory cells. The overall effect is decreased swelling and irritation of the nasal lining.

The appropriate dose of Mommox is set by a qualified healthcare professional based on the patient’s age, severity of symptoms, and clinical response. The prescriber will provide specific instructions on how many sprays to use and how often, and those directions should be followed exactly.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and alternatives with their physician.

To request Mommox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Mommox (mometasone furoate) and fluticasone are both potent nasal corticosteroids with similar anti‑inflammatory actions. Mometasone has a high receptor affinity and a low systemic bioavailability, which may translate into a slightly lower risk of systemic side effects. Clinical efficacy for allergic rhinitis is comparable, and choice often depends on physician preference, patient response, and formulary considerations.

Mommox should be stored at room temperature, typically below 25 °C (77 °F). Keep the spray in its original packaging, protect it from moisture, direct sunlight and excessive heat. Do not freeze the product, and ensure the cap is tightly closed when not in use.

Mommox is administered as a nasal spray. The user should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press down to deliver the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious but rare risks include nasal septal perforation, visual disturbances such as cataracts or increased intra‑ocular pressure, and systemic corticosteroid effects like adrenal suppression when used at high doses for prolonged periods. Patients should report persistent nosebleeds, vision changes, or symptoms of hormonal imbalance to their healthcare provider promptly.

Mommox should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated fungal, viral or bacterial infections of the nasal passages, and in those who have recently undergone nasal surgery unless cleared by a physician.